About: Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective
Creator	Gautam, Singh Gupta, Ashim Gupta, Manu Kadam, Sachin Kashte, Shivaji Rodriguez, Hugo Shraddha, ·
Source	Medline; PMC
abstract	Acute respiratory distress syndrome (ARDS) is the main cause for the COVID-19 infection-related morbidity and mortality. Recent clinical evidences suggest increased level of cytokines and chemokines targeting lung tissue as a prominent etiological factor. The immunomodulatory effect of mesenchymal stem cells (MSCs) as the alternative therapy for the treatment of inflammatory and autoimmune diseases is well known. Several studies have also revealed that similar therapeutic impacts of parent MSCs are also exhibited by MSCs-derived extracellular vesicles (EVs) including exosomes. In this review, we explored the therapeutic potential of both MSCs and exosomes in mitigating the COVID-19 induced cytokine storm as well as promoting the regeneration of alveolar tissue, attributed to the intrinsic cytokines and growth factor present in the secretome. The preliminary studies have demonstrated the safety and efficacy of MSCs and exosomes in mitigating symptoms associated with COVID-19. Thus, they can be used on compassionate basis, owing to their ability to endogenously repair and decrease the inflammatory reactions involved in the morbidity and mortality of COVID-19. However, more preclinical and clinical studies are warranted to understand their mechanism of action and further establish their safety and efficacy.
has issue date	2020-08-11(xsd:dateTime)
bibo:doi	10.1007/s13577-020-00407-w
bibo:pmid	32780299
has license	no-cc
sha1sum (hex)	a6129a72f28200a60c8eac95a02ce4c268cd0221
schema:url	https://doi.org/10.1007/s13577-020-00407-w
resource representing a document's title	Mesenchymal stem cells and exosome therapy for COVID-19: current status and future perspective
has PubMed Central identifier	PMC7418088
has PubMed identifier	32780299
schema:publication	Hum Cell
resource representing a document's body	covid:a6129a72f28200a60c8eac95a02ce4c268cd0221#body_text
is schema:about of	named entity 'preclinical' named entity 'intrinsic' named entity 'impacts' named entity 'COVID-19' named entity 'GROWTH FACTOR' named entity 'THERAPEUTIC' named entity 'COVID-19' covid:arg/a6129a72f28200a60c8eac95a02ce4c268cd0221 named entity 'chemokines' named entity 'involved' named entity 'therapeutic' named entity 'endogenously' named entity 'COVID-19' named entity 'secretome' named entity 'studies' named entity 'tissue' named entity 'MSCs' named entity 'infection' named entity 'cytokines' named entity 'exosomes' named entity 'clinical studies' named entity 'MSCs' named entity 'cytokine storm' named entity 'COVID' named entity 'ARDS' named entity 'COVID-19' named entity 'Acute respiratory distress syndrome' named entity 'morbidity' named entity 'Mesenchymal stem cells' named entity 'COVID-19' named entity 'lung' named entity 'inflammation' named entity 'Hospital' named entity 'COVID-19' named entity 'COVID' named entity 'proinflammatory cytokine' named entity 'respiratory disorders' named entity 'infection' named entity 'homeostasis' named entity 'growth factors' named entity 'endogenous' named entity 'cytokine storm' named entity 'ARDS' named entity 'immunosuppressive' named entity 'pluripotent' named entity 'alloantigens' named entity 'Human Immunodeficiency Virus' named entity 'signalling pathways' named entity 'H7N9' named entity 'open-label' named entity 'mesenchymal stem cells' named entity 'antipyretic' named entity 'ICU' named entity 'bronchoalveolar lavage' named entity 'allogenic' named entity 'immune function' named entity 'infection' named entity 'enzyme' named entity 'MSCs' named entity 'COVID' named entity 'lipid' named entity 'ICU' named entity 'MSCs' named entity 'COVID' named entity 'China' named entity 'secretion' named entity 'COVID-19' named entity 'COVID-19' named entity 'cellular receptors' named entity 'MSCs' named entity 'sepsis' named entity 'infusion' named entity 'ARDS' named entity 'serum' named entity 'stem cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software